Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING Phase 1

REVEAL Biomarkers of Engraftment After Alternative Donor HSCT

NCT03541889 · View on ClinicalTrials.gov ↗

Study Summary

The purpose of this study is to find new tests that could help determine if the newly infused bone marrow cells are growing well after bone marrow transplantation or if new bone marrow cells are needed. The Investigator will use FLT imaging, an investigational imaging test, and collect blood samples to investigate whether the cells are growing well.

Conditions Studied

Interventions

  • DRUG FLT imaging and TK1 blood measurements

Study Locations (4)

Georgia

  • Emory University — Atlanta

Michigan

  • University of Michigan — Ann Arbor

Ohio

  • University Hospital of Cleveland UH Seidman Cancer Center — Cleveland

Oklahoma

  • University of Oklahoma Health Sciences Center, Stephenson Cancer Center — Oklahoma City

Trial Details

FieldValue
Enrollment Target 56 participants
Start Date 2021-02-05
Est. Completion 2027-11
Phase Phase 1

Sponsor

University of Oklahoma

306 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03541889

The ClinicalTrials.gov registry entry for NCT03541889 describes a study currently listed as recruiting. It is categorized as Phase 1, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Oklahoma, which has 306 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Primary Graft Failure appearing as the primary indexed condition, and to 1 intervention — of which FLT imaging and TK1 blood measurements is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT03541889 reports 4 study locations spanning 4 distinct geographic areas — top geographies include Georgia, Michigan, Ohio. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT03541889 about?

NCT03541889 is a clinical study titled "REVEAL Biomarkers of Engraftment After Alternative Donor HSCT". The purpose of this study is to find new tests that could help determine if the newly infused bone marrow cells are growing well after bone marrow transplantation or if new bone marrow cells are needed. The Investigator will use FLT imaging, an investigational imaging test, and collect blood samples...

What is the current status of trial NCT03541889?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2021-02-05. Estimated completion is 2027-11.

What conditions does trial NCT03541889 study?

This clinical trial studies the following conditions: Primary Graft Failure. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT03541889?

The interventions under investigation include: FLT imaging and TK1 blood measurements (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT03541889?

This trial is sponsored by University of Oklahoma, which has 306 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT03541889 being conducted?

This trial has 4 study locations across Georgia, Michigan, Ohio, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial